Kinetics of FGF-23 during Haemodialysis
Research type
Research Study
Full title
Kinetics of Fibroblast growth factor - 23 (FGF-23) during haemodialysis
IRAS ID
169366
Contact name
Elaine Spalding
Contact email
Sponsor organisation
Ayrshire and Arran
Duration of Study in the UK
0 years, 10 months, 0 days
Research summary
Patients with chronic kidney disease (CKD) have abnormal phosphate, vitamin D, calcium and parathyroid hormone (PTH) due to disturbed bone metabolism known as CKD-MBD (CKD - mineral bone disease). The exact pathophysiology leading to this is not well understood.
Fibroblast growth factor (FGF-23), a novel bio marker is believed to play a key role in phosphate homeostasis. FGF-23 levels increases in response to hyperphosphatemia, and by doing so, it promotes excretion of phosphate by kidneys. Other mechanism of actions includes decreasing levels of Vitamin D to limit gut absorption; altering PTH and indirectly affecting calcium, phosphate and Vitamin D levels amongst others.
Dialysis, a key treatment modality in patients with end stage renal disease (ESRD) removes excess phosphate. What happens to phosphate during dialysis has been extensively studied though the effect of dialysis on FGF-23 has never been explored. This research aims to study the kinetics of FGF-23 during dialysis and build a mathematical model using Vis-Sim™.
REC name
West of Scotland REC 4
REC reference
15/WS/0039
Date of REC Opinion
24 Feb 2015
REC opinion
Favourable Opinion